Study wrapper · #584
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.
Editor's note
In a mouse model of elastase-induced abdominal aortic aneurysm, researchers reported that hexarelin, a synthetic growth hormone-releasing peptide, was associated with a smaller infrarenal aortic diameter, less elastin degradation, and preservation of a contractile smooth-muscle-cell phenotype. The study also described reduced inflammatory-cell infiltration, dampened NLRP3 inflammasome activation, and suppressed NF-kappaB signaling. The mechanistic thread, vascular anti-inflammatory action, echoes hexarelin's broader preclinical cardiovascular literature. That said, this is a single animal model with the usual limitations: a chemically induced aneurysm does not reproduce the multifactorial human disease, and durability and dosing translation remain open. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Scientists studied hexarelin, a lab-made peptide, in mice with abdominal aortic aneurysm (a weakening and bulging of the main abdominal artery) triggered by an enzyme. Mice given hexarelin twice daily had a smaller artery diameter and better-preserved elastic tissue in the vessel wall than untreated mice. In hexarelin-treated animals, the muscle cells of the vessel wall kept their normal contractile character, fewer inflammatory cells moved into the wall, and several inflammation-driving signals (the NLRP3 inflammasome, IL-18, and NF-kappaB) were reduced. The authors conclude hexarelin slowed aneurysm development by calming inflammation and stabilizing the vessel-wall muscle cells. The abstract reports no adverse events. These are preclinical findings in mice; human research would be needed before drawing clinical conclusions.